127 related articles for article (PubMed ID: 11218406)
1. [A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Ohkusa T; Watanabe M
Nihon Rinsho; 2001 Feb; 59(2):323-7. PubMed ID: 11218406
[TBL] [Abstract][Full Text] [Related]
2. [Investigation about 3rd line eradication of H. pylori].
Nakagawa S; Kato M; Shimizu Y; Nakagawa M; Asaka M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():466-9. PubMed ID: 16363580
[No Abstract] [Full Text] [Related]
3. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
[No Abstract] [Full Text] [Related]
4. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Shirai N; Furuta T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
[No Abstract] [Full Text] [Related]
5. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
6. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Shirai N; Furuta T; Sugimoto M; Nakamura A
Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
[No Abstract] [Full Text] [Related]
7. [Usefulness of new triple therapy containing PPI].
Tanabe H; Watari J; Shibata N; Satoh T; Yokota K; Kohgo Y
Nihon Rinsho; 2001 Feb; 59(2):314-8. PubMed ID: 11218404
[TBL] [Abstract][Full Text] [Related]
8. [Influence of cytochrome P450 2C19 genetic polymorphism on H. pylori eradication therapy].
Hikichi T; Irisawa A; Abe C; Obara K; Sato Y
Nihon Rinsho; 2005 Nov; 63 Suppl 11():569-72. PubMed ID: 16363603
[No Abstract] [Full Text] [Related]
9. Determinants of non-response in Helicobacter pylori eradication trials.
Klotz U; Treiber G; Schwab M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1471. PubMed ID: 16105147
[No Abstract] [Full Text] [Related]
10. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
11. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
12. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
[TBL] [Abstract][Full Text] [Related]
13. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
Altintas E; Sezgin O; Ulu O; Aydin O; Camdeviren H
World J Gastroenterol; 2004 Jun; 10(11):1656-8. PubMed ID: 15162544
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
15. [Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Inoue K; Sugano K
Nihon Rinsho; 2002 Feb; 60 Suppl 2():460-4. PubMed ID: 11979828
[No Abstract] [Full Text] [Related]
16. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
Schwab M; Schaeffeler E; Klotz U; Treiber G
Clin Pharmacol Ther; 2004 Sep; 76(3):201-9. PubMed ID: 15371981
[TBL] [Abstract][Full Text] [Related]
17. [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Okudaira K; Miura S; Furuta T; Sugimoto M; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():391-6. PubMed ID: 16363566
[No Abstract] [Full Text] [Related]
18. [Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism].
Furuta T; Sugimoto M; Nakamura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():426-33. PubMed ID: 16363573
[No Abstract] [Full Text] [Related]
19. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
Furuta T; Shirai N; Kodaira M; Sugimoto M; Nogaki A; Kuriyama S; Iwaizumi M; Yamade M; Terakawa I; Ohashi K; Ishizaki T; Hishida A
Clin Pharmacol Ther; 2007 Apr; 81(4):521-8. PubMed ID: 17215846
[TBL] [Abstract][Full Text] [Related]
20. [Recent topics on important drugs for H. pylori eradication: Omeprazole].
Kataoka H; Jho T; Itoh M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():333-7. PubMed ID: 16363556
[No Abstract] [Full Text] [Related]
[Next] [New Search]
